69 85

Cited 0 times in

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

DC Field Value Language
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.date.accessioned2021-05-21T16:44:29Z-
dc.date.available2021-05-21T16:44:29Z-
dc.date.issued2020-10-
dc.identifier.issn1598-2998-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182545-
dc.description.abstractPurpose: The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti-programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program. Materials and methods: Previously treated patients with advanced nonsquamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected. Results: Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data. Conclusion: This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherOfficial journal of Korean Cancer Association-
dc.relation.isPartOfCANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleReal-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorSang-We Kim-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorJin Hyung Kang-
dc.contributor.googleauthorMyung-Ju Ahn-
dc.contributor.googleauthorDong-Wan Kim-
dc.contributor.googleauthorYoung-Chul Kim-
dc.contributor.googleauthorJin Soo Lee-
dc.contributor.googleauthorJong-Seok Lee-
dc.contributor.googleauthorSung Yong Lee-
dc.contributor.googleauthorKeon Uk Park-
dc.contributor.googleauthorHo Jung An-
dc.contributor.googleauthorEun Kyung Cho-
dc.contributor.googleauthorTae Won Jang-
dc.contributor.googleauthorBong-Seog Kim-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorSung Sook Lee-
dc.contributor.googleauthorIm-Ii Na-
dc.contributor.googleauthorSeung Soo Yoo-
dc.contributor.googleauthorKi Hyeong Lee-
dc.identifier.doi10.4143/crt.2020.245-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ00453-
dc.identifier.eissn2005-9256-
dc.identifier.pmid32599984-
dc.subject.keywordAnti–PD-1-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordReal-world data-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.citation.volume52-
dc.citation.number4-
dc.citation.startPage1112-
dc.citation.endPage1119-
dc.identifier.bibliographicCitationCANCER RESEARCH AND TREATMENT, Vol.52(4) : 1112-1119, 2020-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.